Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897571764> ?p ?o ?g. }
- W2897571764 endingPage "919" @default.
- W2897571764 startingPage "912" @default.
- W2897571764 abstract "We investigated GDP (gemcitabine, 1000 mg/m2 IV d1, d8; dexamethasone, 40 mg po d1-4; cisplatin, 75 mg/m2 IV d1) combined with romidepsin on days 1 and 8 every 21 days to a maximum of six cycles in a standard 3 + 3, phase I dose escalation trial for patients with relapsed/refractory peripheral T-cell (PTCL) or diffuse large B-cell (DLBCL) lymphoma (NCT01846390). After treating four patients, gemcitabine and romidepsin were given on days 1 and 15 every 28 days. On the 21-day schedule at 6 mg/m2 romidepsin, there were three dose-limiting toxicities (DLTs) among four patients. On the 28-day schedule, there were no DLTs at the 6, 8, or 10 mg/m2 dose. At 12 mg/m2, there were four observed grade 3 DLTs among six evaluable patients. Full doses of GDP can be combined with a recommended phase II romidepsin dose of 10 mg/m2 if given on a day 1, 15 every 28 days schedule." @default.
- W2897571764 created "2018-10-26" @default.
- W2897571764 creator A5006619488 @default.
- W2897571764 creator A5008021351 @default.
- W2897571764 creator A5011619265 @default.
- W2897571764 creator A5017873196 @default.
- W2897571764 creator A5018625771 @default.
- W2897571764 creator A5024269299 @default.
- W2897571764 creator A5027397937 @default.
- W2897571764 creator A5032098740 @default.
- W2897571764 creator A5044632878 @default.
- W2897571764 creator A5045731423 @default.
- W2897571764 creator A5046625416 @default.
- W2897571764 creator A5061856914 @default.
- W2897571764 creator A5062545920 @default.
- W2897571764 creator A5064774673 @default.
- W2897571764 creator A5077619266 @default.
- W2897571764 creator A5083858828 @default.
- W2897571764 creator A5091222951 @default.
- W2897571764 creator A5091653815 @default.
- W2897571764 date "2018-10-10" @default.
- W2897571764 modified "2023-10-16" @default.
- W2897571764 title "A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†" @default.
- W2897571764 cites W1484238615 @default.
- W2897571764 cites W1921071413 @default.
- W2897571764 cites W1993021532 @default.
- W2897571764 cites W2011118089 @default.
- W2897571764 cites W2011887454 @default.
- W2897571764 cites W2032936106 @default.
- W2897571764 cites W2080029028 @default.
- W2897571764 cites W2109716912 @default.
- W2897571764 cites W2114594238 @default.
- W2897571764 cites W2116068882 @default.
- W2897571764 cites W2123576646 @default.
- W2897571764 cites W2123807140 @default.
- W2897571764 cites W2133201432 @default.
- W2897571764 cites W2133345449 @default.
- W2897571764 cites W2134210438 @default.
- W2897571764 cites W2146112074 @default.
- W2897571764 cites W2156517973 @default.
- W2897571764 cites W2171873783 @default.
- W2897571764 cites W2280483683 @default.
- W2897571764 cites W2312198114 @default.
- W2897571764 cites W2317505970 @default.
- W2897571764 cites W2335828047 @default.
- W2897571764 cites W2416844197 @default.
- W2897571764 cites W2484616545 @default.
- W2897571764 cites W2492170142 @default.
- W2897571764 cites W2542819394 @default.
- W2897571764 cites W2552767925 @default.
- W2897571764 cites W2560853463 @default.
- W2897571764 cites W2580493818 @default.
- W2897571764 cites W2609884290 @default.
- W2897571764 cites W2616844199 @default.
- W2897571764 cites W2621905479 @default.
- W2897571764 cites W2753607561 @default.
- W2897571764 cites W2781311956 @default.
- W2897571764 cites W2790413110 @default.
- W2897571764 cites W2808492038 @default.
- W2897571764 doi "https://doi.org/10.1080/10428194.2018.1515937" @default.
- W2897571764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30301414" @default.
- W2897571764 hasPublicationYear "2018" @default.
- W2897571764 type Work @default.
- W2897571764 sameAs 2897571764 @default.
- W2897571764 citedByCount "18" @default.
- W2897571764 countsByYear W28975717642019 @default.
- W2897571764 countsByYear W28975717642020 @default.
- W2897571764 countsByYear W28975717642021 @default.
- W2897571764 countsByYear W28975717642022 @default.
- W2897571764 countsByYear W28975717642023 @default.
- W2897571764 crossrefType "journal-article" @default.
- W2897571764 hasAuthorship W2897571764A5006619488 @default.
- W2897571764 hasAuthorship W2897571764A5008021351 @default.
- W2897571764 hasAuthorship W2897571764A5011619265 @default.
- W2897571764 hasAuthorship W2897571764A5017873196 @default.
- W2897571764 hasAuthorship W2897571764A5018625771 @default.
- W2897571764 hasAuthorship W2897571764A5024269299 @default.
- W2897571764 hasAuthorship W2897571764A5027397937 @default.
- W2897571764 hasAuthorship W2897571764A5032098740 @default.
- W2897571764 hasAuthorship W2897571764A5044632878 @default.
- W2897571764 hasAuthorship W2897571764A5045731423 @default.
- W2897571764 hasAuthorship W2897571764A5046625416 @default.
- W2897571764 hasAuthorship W2897571764A5061856914 @default.
- W2897571764 hasAuthorship W2897571764A5062545920 @default.
- W2897571764 hasAuthorship W2897571764A5064774673 @default.
- W2897571764 hasAuthorship W2897571764A5077619266 @default.
- W2897571764 hasAuthorship W2897571764A5083858828 @default.
- W2897571764 hasAuthorship W2897571764A5091222951 @default.
- W2897571764 hasAuthorship W2897571764A5091653815 @default.
- W2897571764 hasConcept C104317684 @default.
- W2897571764 hasConcept C121608353 @default.
- W2897571764 hasConcept C126322002 @default.
- W2897571764 hasConcept C143998085 @default.
- W2897571764 hasConcept C185592680 @default.
- W2897571764 hasConcept C203014093 @default.
- W2897571764 hasConcept C2776090121 @default.
- W2897571764 hasConcept C2776694085 @default.
- W2897571764 hasConcept C2777891184 @default.